期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

钙通道阻滞剂联合血管紧张素Ⅱ受体阻滞剂在脑卒中预防中的临床意义 被引量：1

Preventive Effect of Combined Calcium Channel Blockers and Angiotensin Receptor Blockers in Stroke
下载PDF
导出
摘要 钙通道阻滞剂及血管紧张素Ⅱ受体阻滞剂均为降压达标且具预防脑卒中发生作用的降压药物。两类药物联用降压作用更加明显且在预防终点事件尤其在脑卒中方面应具有符合逻辑的优势,现综述两类药物预防脑卒中的循证证据、联合用药的作用及可能机制。 Calcium channel blockers and angiotensin Ⅱ receptor blockers,represent the two antihypertensive drug classes with the strongest supportable data for the prevention of stroke.A combination of these two antihypertensive classes represents should be a logical approach.Here we review data of clinical evidence both the two kind of drugs in prevention of stroke and analysis the potential mechanism.
作者 戴秋艳
机构地区 上海交通大学附属第一人民医院心内科
出处 《心血管病学进展》 CAS 2011年第1期20-24,共5页 Advances in Cardiovascular Diseases
关键词 钙通道阻滞剂 血管紧张素Ⅱ受体阻滞剂 脑卒中 calcium channel blockers angiotensin Ⅱ receptor blockers stroke
分类号 R743 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献30

  • 1Liu M, Wu B, Wang WZ, et al. Stroke in China: epidemiology, preventionl and management strategies [ J ]. Lancet Neurol,2007,6 : 456-464.
  • 2Feigin VL, Lawes CM, Bennett DA, et al. Worldwide stroke incidence and eally case fatality reported in 56 population-based studies: a systematic review [ J ]. Lancet Neurol,2009, 8: 355-369.
  • 3Dbamoon MS, Elkind MS. Inclusion of stroke as an outcome and risk equivalent in risk scores for primary and secondary prevention of vascular disease[ J]. Cir- culation, 2010,121 : 2071-2078.
  • 4Woodward M, Huxley H, Lam TH, et al. A comparison of the associations be- tween risk factors and cardiovascular disease in Asia and Australasia. Asia Pacif- ic Cohort Studies Collaboration[ J ]. Eur J Cardiovasc Prey Rehabil, 2005 , 12 (5) :484-491.
  • 5O'Donnell MJ, International Stroke Trial Collaborative Group . The International Stroke Trial (IST) : a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke[ J ]. Lancet,2010, available at: http://www. thelancet. com.
  • 6Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the pre- vention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies [ J ]. B MJ,2009, 338 :b1665.
  • 7Turnbull F, Blood Pressure Lowering Treatment Trialists" Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events : re- sults of prospectively-designed overvlews of randomised trials [ J ]. Lancet, 2003,362 : 1527-1535.
  • 8Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes : a meta-analysis of 175,634 patients [ J ]. J Hyper- tens,2009, 27:1136-1151.
  • 9Leenen FH, Nwachuku CE, Black HR, et al. ALLHAT:clinical events in high- risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lower- ing treatment to prevent heart attack trial[ J ]. Hypertension, 2006,48:374-384.
  • 10Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodip- ine : the VALUE randomised trial[ J]. Lancet, 2004,363 (9426) :2022-2031.

同被引文献9

引证文献1

二级引证文献3

心血管病学进展
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部